Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application PCT/US2013/036193, filed Apr 11, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,394,283 | Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor In force · High confidence UsedRemaining | Epizyme, Inc. | In force | High confidence | ||
| US 9,872,862 | Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor In force · High confidence | Epizyme, Inc. | In force | High confidence | ||
| US 10,245,269 | Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor In force · High confidence | Epizyme, Inc. | In force | High confidence | ||
| US 10,821,113 | Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor In force · High confidence | Epizyme, Inc. | In force | High confidence | ||
| US 11,491,163 | Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor In force · High confidence | Epizyme, Inc. | In force | High confidence | ||
| US 12,251,386 | Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor In force · High confidence | Epizyme, Inc. | In force | High confidence | ||
| Application 19/053,007 | Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor Pending Not granted | Eisai R&D Management Co., Ltd. | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Epizyme, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.